340B Report Publisher and CEO: Momentum for 340B Protections Is Growing

Interior of Washington State House of Representatives chamber
340B healthcare providers have turned to the states to address challenges to the drug discount program, 340B Report Publisher and CEO Ted Slafsky says.

Safety net healthcare providers increasingly have turned to the states to address challenges to the 340B program, 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.

“In just four years, an

Read More »

NEJM Article Says HIV Prevention Should Rely Less on 340B Revenue

screenshot of a New England Journal of Medicine article
An opinion article in the New England Journal of Medicine says overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options. Some HIV/AIDS care providers say high drug prices are the problem, not 340B.

Overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options, “with dire consequences for [preexposure prophylaxis] PrEP access, impact, and equity,” says an opinion article published last weekend in

Read More »

BMS and Merck Announce Refunds for 340B Overcharges

an extended hand holding a 100 dollar bill
BMS and Merck—both for the second time this year—are giving 340B covered entities refunds for overcharges on select products.

Drug manufacturers Bristol Myers Squibb (BMS) and Merck are giving 340B covered entities refunds for overcharges on select products, according to public notices by the companies posted on the U.S. Health Resources and Services Administration (HRSA) website.

BMS

For the

Read More »

With Talk of Legislation Heating Up, PhRMA Seeks a New 340B Policy Director

PhRMA wordmark repeated on a background
PhRMA is seeking a new director for its policy and research team to help develop and lead implementation of work on 340B.

Pharmaceutical Research and Manufacturers of America (PhRMA) is seeking a new director for its policy and research team to help develop and lead implementation of work on 340B and related hospital cost and affordability issues, according to an employment solicitation

Read More »

340B ADR Proposed Rule Remains at White House 5 Months Past Expected Publication Date

Pages of a calendar
A proposed replacement for the 340B administrative dispute resolution process has been under White House review for more than six months.

A proposed replacement for the 340B administrative dispute resolution (ADR) process has been under White House review for more than half a year. It seems to be no closer to publication for notice and comment than it was when it

Read More »

CMS Asks Court Again to Dismiss 340B Health Centers’ Suit Over Medicaid Drug Benefits Transfer

A state of California benefits identification card
CMS again asked a federal district court to dismiss California 340B health centers’ lawsuit over the state’s transfer of Medicaid managed care drug benefits to Medicaid fee for service.

The U.S. Centers for Medicare & Medicaid Services (CMS) last week again asked a federal district court in Sacramento to dismiss a group of California health centers’ claims for relief over CMS’s approval of the state’s transfer of Medicaid managed

Read More »

Tennessee Health System Strikes Back Against DOJ Claims It Paid for Referrals to Boost 340B Revenue

Methodist University Hospital, Methodist Le Bonheur Healthcare building
Methodist Le Bonheur Healthcare disputes U.S. Justice Department claims that the health system's agreements under the system’s affiliation with a private oncology practice were “a fiction” perpetuated partially to let the system “realize profits from the 340B program.”

A Tennessee health system last week denied U.S. Justice Department (DOJ) allegations that agreements under the system’s seven-year affiliation with a private oncology practice were “a fiction” perpetuated partially to let the system “realize profits from the 340B program.”

Methodist

Read More »

Provider Groups File Appellate Briefs in Key 340B Contract Pharmacy Cases

US court of appeals for the DC circuit courtroom interior
Groups representing health centers, HIV/AIDS clinics, and hospitals filed briefs in key 340B contract pharmacy cases in federal appeals courts in Washington, D.C., and Philadelphia.

Groups representing health centers, HIV/AIDS clinics, and hospitals asked federal appeals courts in Philadelphia and Washington, D.C., this week to hold that drug manufacturers must give covered entities 340B discounts on drugs when entities use contract pharmacies to fill prescriptions

Read More »

U.S. Uninsured Rate Dipped Slightly in 2021 to 9.2% but Rates for Hispanics and Blacks Remain High

bar chart showing percentage of U.S. population uninsured and insured by age group
The U.S. uninsured rate fell slightly in 2021 to 9.2%, down from 9.7% in 2020, new data from the National Center for Health Statistics (NCHS) show.

The U.S. uninsured rate fell slightly in 2021 to 9.2% (about 30 million people), down from 9.7% (about 31.6 million people) in 2020, the National Center for Health Statistics (NCHS) reports.

NCHS released this and related health insurance coverage findings earlier

Read More »

25 States Say Drug Companies’ 340B Contract Pharmacy Actions Are Illegal and Harm Public Health

excerpt of amicus brief for 340B drug pricing program
An excerpt from one of the two friend of the court briefs that 25 states filed in pivotal 340B contract pharmacy litigation in federal appeals courts.

Yesterday, 340B Report broke the news that a group of 25 states from blue bastions such as Connecticut and Maryland to red states such as Arkansas and Mississippi weighed in favor of the federal government’s effort to punish drug manufacturer

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live